The Reciprocal Relations Between Psychosocial Characteristics and the Progression of Vestibulodynia

Sponsor
Meir Medical Center (Other)
Overall Status
Completed
CT.gov ID
NCT02892214
Collaborator
(none)
113
1
60
1.9

Study Details

Study Description

Brief Summary

The proposed study will evaluate how personality characteristics, cognitive factors and the emotional and behavioral responses of patients with provoked vestibulodynia (localized provoked vulvodynia) influence the natural history of the syndrome, patients' adherence to therapeutic interventions, provoked pain levels, pelvic floor rehabilitation, emotional health and sexual functioning.

Condition or Disease Intervention/Treatment Phase
  • Procedure: Pelvic floor physical therapy
  • Drug: estriol cream (ovestin)
  • Procedure: Low-level-laser therapy

Detailed Description

Provoked vestibulodynia (PVD) is the term describing a syndrome of provoked, localized allodynia of the vestibule of the vulva, not explained by another condition, and lasting more than 3 months. PVD is not a defined disease but rather a symptom. It is thought that PVD represent a group of distinct disorders that have been classified together because they produce pain in the same anatomic location.

Studies found that different factors such as genetic, inflammation, recurrent vaginitis, allergy, trauma, emotional and neural may be involved in the development of PVD.

Treatment of PVD is generally predicated on a trial and error basis, because the pathogenesis is not defined. The result is that many forms of therapeutic interventions have been used, yet the evidence remains largely inconclusive, the response rates varies considerably, and many women do not respond to any of the treatments. It is therefore important to recognize which factors mediate the syndrome's severity, and influence the effectiveness of treatments.

The proposed study will evaluate how different patients' characteristics (personality, cognitive) and responses (emotional and behavioral) influence the natural history of the syndrome and the response to treatment. The study is based on the bio-psycho-social model and the adult attachment theory, which integrates psychosocial factors to define susceptibility to acquire pain disorders and predict response to therapy. According to this model, choosing effective coping strategy during a crisis and receiving support from a spouse are vital for recovery.

The study aim to:
  1. Characterize interactions between attachment patterns, personality types, cognitive factors (catastrophization, coherence, and partner's support), emotional factors (coping strategies, emotional stress and satisfaction from intimate relationship) to pain levels, pelvic floor hypertonicity, sexual function and patient's emotional health.

  2. Examine whether treatments' results are influenced by personality, relationship, cognitive, emotional and behavioral characteristics of the patient.

  3. Recognize factors that influence the extent of adherence to treatment.

  4. Characterize patients' profile in regard to successful outcome.

Methods Patients will be recruited from the clinic for vulvovaginal disorders in Clalit Healthcare services in Jerusalem. The diagnostic procedures, patients' sub-classification and the proposed treatments in the current protocol are identical to those currently used in the clinic. Each patient will undergo a standard evaluation which includes: detailed history intake, vulvar and vaginal examination, evaluation of vestibular tenderness (Q tip test), pelvic floor musculature tenderness examination, vaginal pH measurement, saline and 10% potassium hydroxide microscopy, yeast and bacterial cultures and STD screening.

Patients who fulfill diagnostic criteria of PVD and who will be willing to participate in the study will be asked to sign an informed consent and complete the following self-administered intake questionnaires:

  • Socio-demographic questionnaire (age, marital status, religios, PVD onset, health status, education etc.)

  • Close Relations Experiences questionnaire

  • Five Factor Inventory -NEO-FFI

  • Pain catastrophizing questionnaire

  • Sense of Coherence Scale

  • Ways of giving support questionnaire

  • COPE -Multidimensional Coping Inventory

  • Semantic Differential Measure of Marital Satisfaction

  • PSS-10 - Perceived Stress Scale

  • FSFI-Female Sexual Function Index

Instructions for treatment will be given in regards to the diagnosis. Patients will be instructed to schedule follow-up appointments at 3,6,9, and 12 months. During follow-up appointments they will be assessed in regard to vestibular tenderness (using various parameters), as well as by the same questionnaires. Additional treatment will be recommended according to medical status, in an identical way to this routinely used in the clinic.

Study Design

Study Type:
Observational [Patient Registry]
Actual Enrollment :
113 participants
Observational Model:
Case-Only
Time Perspective:
Prospective
Official Title:
The Reciprocal Relations Between Psychosocial Characteristics and the Progression of Vestibulodynia, and the Mental Health of the Patient
Actual Study Start Date :
Nov 30, 2016
Actual Primary Completion Date :
Dec 1, 2020
Actual Study Completion Date :
Dec 1, 2021

Arms and Interventions

Arm Intervention/Treatment
Hypertonic pelvic muscle dysfunction

In this subgroup, pelvic floor (PF) muscles become tight and tender. Typically, the pain is much worse at 4-8 o'clock position of the vestibule with minimal or no pain in the upper vestibule.

Procedure: Pelvic floor physical therapy

Hormonally mediated PVD

The pain began while taking hormonal contraceptive or other medications that affect hormones, after removal of ovaries, breastfeeding or menopause. The entire vestibule is tender and vestibular mucosa is often dry and thin.

Drug: estriol cream (ovestin)

Neuroproliferative PVD

In this condition, we speculate that women have an increased number of nociceptors in the vestibular mucosa. Pain is primary and there is tenderness of the entire vestibule.

Procedure: Low-level-laser therapy

Outcome Measures

Primary Outcome Measures

  1. Change of measure of Q tip test assessing pain intensity [Change in measure between recruitment to 3 months, 6 months , 9 months and 12 months]

    The exam is performed by touching the vestibule with a cotton-tip applicator in 6 defined points (2,5,6,7, 10 and 12),while the patient is being asked to rate the intensity of pain verbally from 0 to 10 at each point.

Secondary Outcome Measures

  1. Measurement of vestibular tenderness using a vulvar algesiometer [Every 3 months for 1 year- 0, 3 months, 6 months, 9 months and 12 months.]

  2. Change of pain using Visual analog scale [Change in VAS between recruitment to 3 months, 6 months , 9 months and 12 months]

  3. Adherence to therapy [Every 3 months for 1 year- 0, 3 months, 6 months, 9 months and 12 months.]

    Adherence to therapy will be assessed by calculating attendance to planed appointments (physical therapy, medical appointments and LLL treatments)

  4. Female sexual function index questionnaire [Every 3 months for 1 year- 0, 3 months, 6 months, 9 months and 12 months.]

  5. Pelvic floor hypertonicity measurements [Every 3 months for 1 year- 0, 3 months, 6 months, 9 months and 12 months.]

    Pelvic floor muscle tonicity will be evaluated using manual palpation of the muscles by the physician.

  6. Brief Symptom Inventory-18 questionnaire (evaluating emotional symptoms) [Every 3 months for 1 year- 0, 3 months, 6 months, 9 months and 12 months.]

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years to 45 Years
Sexes Eligible for Study:
Female
Accepts Healthy Volunteers:
Yes
Inclusion Criteria:
  1. A history of 3 months or more of vulvar pain suggestive of PVD, i.e. symptoms of pain on vaginal penetration (insertional dyspareunia and/or pain with tampon insertion).

  2. On exam, tenderness localized within the vestibule when being touched with a cotton-tip applicator.

  3. No identifiable cause for the pain, such as vulvovaginal candidiasis, vaginal atrophy, desquamative inflammatory vaginitis (DIV), herpes, dermatitis or vulvar dystrophy.

Exclusion Criteria:
  1. other causes for vulvar pain

  2. pregnancy or a planned pregnancy in the upcoming year

  3. diagnosis of chronic disease that may affect central nervous system or general function.

  4. usage of psychiatric medications or those affecting pain modulation.

  5. unprovoked or mixed vulvodynia

Contacts and Locations

Locations

Site City State Country Postal Code
1 Merkaz Briot Haisha, Ramat Eshkol Jerusalem Israel

Sponsors and Collaborators

  • Meir Medical Center

Investigators

None specified.

Study Documents (Full-Text)

None provided.

More Information

Publications

Responsible Party:
Ahinoam Lev-Sagie, MD, Meir Medical Center
ClinicalTrials.gov Identifier:
NCT02892214
Other Study ID Numbers:
  • 0089-16-COM1
First Posted:
Sep 8, 2016
Last Update Posted:
Apr 8, 2022
Last Verified:
Apr 1, 2022
Individual Participant Data (IPD) Sharing Statement:
No
Plan to Share IPD:
No
Additional relevant MeSH terms:

Study Results

No Results Posted as of Apr 8, 2022